91 related articles for article (PubMed ID: 23281044)
1. Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.
Le LT; Vu HL; Naud-Martin D; Bombled M; Nguyen CH; Molla A
ChemMedChem; 2013 Feb; 8(2):289-96. PubMed ID: 23281044
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.
Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ
J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538
[TBL] [Abstract][Full Text] [Related]
3. Discovery of benzo[e]pyridoindolones as kinase inhibitors that disrupt mitosis exit while erasing AMPK-Thr172 phosphorylation on the spindle.
Le LT; Couvet M; Favier B; Coll JL; Nguyen CH; Molla A
Oncotarget; 2015 Sep; 6(26):22152-66. PubMed ID: 26247630
[TBL] [Abstract][Full Text] [Related]
4. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
6. Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases.
Hoang TM; Favier B; Valette A; Barette C; Nguyen CH; Lafanechère L; Grierson DS; Dimitrov S; Molla A
Cell Cycle; 2009 Mar; 8(5):765-72. PubMed ID: 19221479
[TBL] [Abstract][Full Text] [Related]
7. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
Fu RG; You QD; Yang L; Wu WT; Jiang C; Xu XL
Bioorg Med Chem; 2010 Nov; 18(22):8035-43. PubMed ID: 20934346
[TBL] [Abstract][Full Text] [Related]
9. Development and biological evaluation of a novel aurora A kinase inhibitor.
Sardon T; Cottin T; Xu J; Giannis A; Vernos I
Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
[TBL] [Abstract][Full Text] [Related]
10. Aurora A and B kinases as targets for cancer: will they be selective for tumors?
Matthews N; Visintin C; Hartzoulakis B; Jarvis A; Selwood DL
Expert Rev Anticancer Ther; 2006 Jan; 6(1):109-20. PubMed ID: 16375648
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
12. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Fancelli D; Moll J; Varasi M; Bravo R; Artico R; Berta D; Bindi S; Cameron A; Candiani I; Cappella P; Carpinelli P; Croci W; Forte B; Giorgini ML; Klapwijk J; Marsiglio A; Pesenti E; Rocchetti M; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Zugnoni P; Vianello P
J Med Chem; 2006 Nov; 49(24):7247-51. PubMed ID: 17125279
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
[TBL] [Abstract][Full Text] [Related]
15. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
16. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
18. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Adams ND; Adams JL; Burgess JL; Chaudhari AM; Copeland RA; Donatelli CA; Drewry DH; Fisher KE; Hamajima T; Hardwicke MA; Huffman WF; Koretke-Brown KK; Lai ZV; McDonald OB; Nakamura H; Newlander KA; Oleykowski CA; Parrish CA; Patrick DR; Plant R; Sarpong MA; Sasaki K; Schmidt SJ; Silva DJ; Sutton D; Tang J; Thompson CS; Tummino PJ; Wang JC; Xiang H; Yang J; Dhanak D
J Med Chem; 2010 May; 53(10):3973-4001. PubMed ID: 20420387
[TBL] [Abstract][Full Text] [Related]
19. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
20. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
